

# ASCO 2017 Annual Meeting

Making a Difference in Cancer Care With You

McCormick Place, Chicago, IL, June 2 – 5, 2017

Oral Presentations			
Authors	Title	Abstract #	Date/Time
Sylvia Adams, Peter Schmid, Hope S. Rugo, Eric P. Winer, Delphine Loirat, Ahmad Awada, David W. Cescon, Hiroji Iwata, Mario Campone, Rita Nanda, Rina Hui, Giuseppe Curigliano, Deborah Toppmeyer, <b>Joyce O'Shaughnessy</b> , Sherene Loi, Shani Paluch-Shimon, Deborah Card, Jing Zhao, Vassiliki Karantza, Javier Cortes.	Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A.	USOR Study # 15072 Abstract # 1008	Saturday June 3, 1:15 PM to 4:15 PM; Hall D1
Ian Flinn, Richard van der Jagt, Julie E. Chang, Peter Wood, Tim E. Hawkins, David MacDonald, Judith Trotman, David Simpson, <b>Kathryn S. Kolibaba</b> , Samar Issa, Doreen M. Hallman, Ling Chen, <b>John M. Burke</b> .	First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP: Results of the BRIGHT 5-year follow-up study.	USOR Study # 7152 Abstract # 7500	Saturday June 3, 3:00 PM to 6:00 PM; S100bc
<b>David Jacob Andorsky</b> , Abdulraheem Yacoub, <b>Jason M. Melear</b> , Morton Coleman, <b>Kathryn S. Kolibaba</b> , <b>Heather Dawn Brooks</b> , Jacob D. Bitran, <b>Suzanne R. Fanning</b> , Frederick Lansigan, Justin L. Ricker, Kenneth A. Foon, Dongfang Liu, Mary Llorente, Jiahui Li, <b>Jeff Porter Sharman</b> .	Phase IIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).	USOR Study # 13064 Abstract # 7502	Saturday June 3, 3:00 PM to 6:00 PM; S100bc
<b>Jeff Porter Sharman</b> , Danielle M. Brander, Anthony R. Mato, Suman Kambhampati, <b>John M. Burke</b> , Frederick Lansigan, Marshall T. Schreeder, Scott D. Lunin, Nilanjan Ghosh, <b>Alexander Zweibach</b> , Mikhail Shtivelband, Patrick M. Travis, Jason Claud Chandler, <b>Kathryn S. Kolibaba</b> , Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Ian Flinn.	Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 stud.	USOR Study # 14206 Abstract # 7504	Saturday June 3, 3:00 PM to 6:00 PM; S100bc
Sunil R. Hingorani, Andrea J. Bullock, Tara Elisabeth Seery, Lei Zheng, Darren Sigal, Paul S. Ritch, <b>Fadi S. Braiteh</b> , Mark Zalupski, Nathan Bahary, William Proctor Harris, Jie Pu, Carrie Aldrich, Sihem Khelifa, Xionghua W. Wu, Joaquina Baranda, Ping Jiang, Andrew Eugene Hendifar.	Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA).	USOR Study # 12237 Abstract # 4008	Sunday June 4, 8:00 AM to 11:00 AM; Hall D2

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

**Learn More:**

Online: [usoncology.com/research](http://usoncology.com/research)

Email: [researchopportunities@mckesson.com](mailto:researchopportunities@mckesson.com)

Phone: (281) 863-1000

Poster Discussions			
Authors	Title	Abstract #	Date/Time
Mehra Golshan, Sibylle Loibl, Jens Bodo Huober, <b>Joyce O'Shaughnessy</b> , Hope S. Rugo, Norman Wolmark, Mark D. McKee, David Maag, Danielle Marie Sullivan, Vincent L. Giranda, Xuan Liu, Gunter Von Minckwitz, Charles E. Geyer, William M. Sikov, Michael Untch.	Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).	<b>USOR Study # 12152</b> Abstract # 514	Sunday June 4, 8:00 AM to 11:30 AM; Hall A Sunday June 4, 11:30 AM to 12:45 PM; Hall D2
Charles E. Geyer, <b>Joyce O'Shaughnessy</b> , Michael Untch, William Sikov, Hope S. Rugo, Mark D. McKee, Jens Bodo Huober, Mehra Golshan, Vincent L. Giranda, Gunter Von Minckwitz, David Maag, Danielle Marie Sullivan, Norman Wolmark, <b>Kristi McIntyre</b> , Jose Juan Ponce Lorenzo, Otto Metzger Filho, Priya Rastogi, William Fraser Symmans, Xuan Liu, Sibylle Loibl.	Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).	<b>USOR Study # 12152</b> Abstract # 520	Sunday June 4, 8:00 AM to 11:30 AM; Hall A Sunday June 4, 11:30 AM to 12:45 PM; Hall D2
Sunil Verma, <b>Joyce O'Shaughnessy</b> , Howard A. Burris, Mario Campone, Emilio Alba, David Chandiwana, Stephanie Manson, Santosh C. Sutradhar, Mauricio Monaco, Wolfgang Janni.	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.	<b>USOR Study # 13146</b> Abstract # 1020	Sunday June 4, 8:00 AM to 11:30 AM; Hall A Sunday June 4, 4:45 PM to 6:00 PM; Hall B1

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Teresa Mercade Macarulla, Jens T. Siveke, Andrea Wang-Gillam, Chung-Pin Li, Gyorgy Bodoky, Andrew Peter Dean, Shan Yanshen, Gayle S. Jameson, Kyung-Hun Lee, Jean-Frédéric Blanc, Chang-Fang Chiu, Gilberto Schwartzmann, <b>Fadi S. Braiteh</b> , David Cunningham, Li-Tzong Chen, <b>Daniel D. Von Hoff</b> , Khalid Kevin Mamlouk, Parul Bhargava, Floris A. de Jong, Richard Hubner.	Subgroup analysis by prior lines of metastatic therapy (mtx) in NAPOLI-1: A global, randomized phase 3 study of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV), vs. 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy.	<b>USOR Study # 11031</b> Abstract # 4127	Saturday June 3, 8:00 AM to 11:30 AM; Hall A
<b>Carlos Becerra</b> , Wahid Tewfik Hanna, <b>Stephen Lane Richey</b> , Gregory Michael Cote, Scott Andrew Laurie, Adrian Langleben, Yuan Gao, Wei Li, Youzhi Li, Matthew Hitron, Chiang Li.	A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated non-squamous non-small cell lung cancer.	<b>USOR Study # 13053</b> Abstract # 9052	Saturday June 3, 8:00 AM to 11:30 AM; Hall A
Corey J. Langer, Eric C. Anderson, <b>Robert M. Jotte</b> , Jonathan Wade Goldman, Daniel Ernest Haggstrom, <b>Matei Paul Socoteanu</b> , <b>David A. Smith</b> , <b>Christopher Dakhil</b> , <b>Kartik Konduri</b> , Edward S. Kim, Teng Jin Ong, Alexandra Sanford, Katayoun Amiri, Jared Weiss.	ABOUND.70+: Safety and efficacy of nab-paclitaxel/carboplatin (nab-P/C) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).	<b>USOR Study # 14034</b> Abstract # 9059	Saturday June 3, 8:00 AM to 11:30 AM; Hall A
Bassel F. El-Rayes, <b>Donald A. Richards</b> , <b>Allen Lee Cohn</b> , <b>Stephen Lane Richey</b> , Trevor Feinstein, Madappa N. Kundranda, Anthony B. El-Khoueiry, <b>Jason M. Melear</b> , <b>Fadi S. Braiteh</b> , Matthew Hitron, Waldo Feliu Ortuzar, Waheed Khan, Bo Xu, Wei Li, Youzhi Li, C J Li.	BBI608-503-103HCC: A phase Ib/II clinical study of napabucasin (BBI608) in combination with sorafenib or amcasertib (BBI503) in combination with sorafenib (Sor) in adult patients with hepatocellular carcinoma (HCC).	<b>USOR Study # 14148</b> Abstract # 4077	Saturday June 3, 8:00 AM to 11:30 AM; Hall A

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Caio Max S. Rocha Lima, Patrick J. Roberts, Victor M. Priego, Stephen G. Divers, Melanie B. Thomas, Ralph V. Bocchia, Katie Stabler, Elizabeth Andrews, Rajesh K. Malik, Raid Aljumaily, John Turner Hamm, Vi Kien Chiu, <b>Donald A. Richards</b> , Petros Nikolinakos, Maen A. Hussein, Steven Robert Schuster, Robert John Hoyer, Geoffrey Shapiro, Konstantin H. Dragnev, Taofeek Kunle Owonikoko.	Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.	<b>USOR Study # 15068</b> Abstract # 8568	Saturday June 3, 8:00 AM to 11:30 AM; Hall A
Gini F. Fleming, Leisha A. Emens, Joseph Paul Eder, Erika Paige Hamilton, Joyce F. Liu, Bo Liu, Luciana Molinero, Marcella Fassio, Carol O'Hear, <b>Fadi S. Braiteh</b> .	Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC).	<b>USOR Study # 12008</b> Abstract # 5585	Saturday June 3, 1:15 PM to 4:45 PM; Hall A
<b>William Jeffery Edenfield</b> , <b>Carlos Becerra</b> , <b>Fadi S. Braiteh</b> , <b>Alexander I. Spira</b> , Ryan J. Sullivan, Timothy J. Panella, Wei Li, Janet Huang, Youzhi Li, Keith Flaherty, Matthew Hitron, Chiang Li.	A phase 1b study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.	<b>USOR Study # 13053</b> Abstract # 9553	Saturday June 3, 1:15 PM to 4:45 PM; Hall A
<b>Carlos Becerra</b> , Agustin A. Garcia, John L. Hays, Michael W. Method, <b>Stephen Lane Richey</b> , Adrian Langleben, <b>Donald A. Richards</b> , Gregory Michael Cote, Kimiko Kossler, Wei Li, Youzhi Li, Matthew Hitron, Chiang Li.	A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer.	<b>USOR Study # 13053</b> Abstract # 5548	Saturday June 3, 1:15 PM to 4:45 PM; Hall A
Julie R. Nangia, Tao Wang, <b>Cynthia R. C. Osborne</b> , Polly Ann Niravath, Kristen Otte, Steven W. Papish, <b>Frankie Ann Holmes</b> , Jame Abraham, Shari Beth Goldfarb, <b>Jay G. Courtright</b> , Richard Paxman, Mari Rude, Susan G. Hilsenbeck, C. Kent Osborne, Mothaffar F. Rimawi.	Scalp Cooling Alopecia Prevention trial (SCALP) for patients with early stage breast cancer.	<b>USOR Study # 13177</b> Abstract # 10088	Saturday June 3, 1:15 PM to 4:45 PM; Hall A
Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch-Shimon, Mario Campone, Katarina Petrakova, Kimberly L. Blackwell, Eric P. Winer, Wolfgang Janni, Sunil Verma, Pier Franco Conte, Carlos L. Arteaga, David A. Cameron, Fengjuan Xuan, Michelle Kristine Miller, Caroline Germa, Samit Hirawat, <b>Joyce O'Shaughnessy</b> .	Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).	<b>USOR Study # 13146</b> Abstract # 1038	Sunday June 4, 8:00 AM to 11:30 AM; Hall A
Wolfgang Janni, Howard A. Burris, Kimberly L. Blackwell, Lowell L. Hart, Arlene Chan, Arnd Nusch, Olga Nikolaevna Burdaeva, Emilio Alba, Denise A. Yardley, Thomas Denis Bachelot, Miguel J. Gil Gil, <b>Donald A. Richards</b> , Joseph A. Sparano, Joseph Gergi Kattan, Hugues Pierre Bourgeois, Fadi Rafic El Karak, Bhuvaneswari Ramaswamy, Santosh C. Sutradhar, Michelle Kristine Miller, Pier Franco Conte.	First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.	<b>USOR Study # 13146</b> Abstract # 1047	Sunday June 4, 8:00 AM to 11:30 AM; Hall A
Thomas Powles, Juergen E. Gschwend, Yohann Loriot, Joaquim Bellmunt, Lajos Gecezi, Christof Vulsteke, Mahmoud Abdelsalam, Rustem Gafanov, Woo Kyun Bae, Janos Revesz, Yoshiaki Yamamoto, Urbano Anido, Wen-Pin Su, <b>Mark T. Fleming</b> , <b>Maurice Markus</b> , Dai Feng, Christian Heinrich Poehlein, Ajai Alva.	Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.	<b>USOR Study # 16054</b> Abstract # TPS4590	Sunday June 4, 8:00 AM to 11:30 AM; Hall A

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

Poster Presentations			
Authors	Title	Abstract #	Date/Time
Robert J. Motzer, Viktor Grünwald, <b>Thomas E. Hutson</b> , Camillo Porta, Thomas Powles, Masatoshi Eto, Corina E Dutcus, Mahadi Ali Baig, Lea Dutta, Di Li, Toni K. Choueiri.	A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC).	<b>USOR Study # 16145</b> Abstract # TPS4595	Sunday June 4, 8:00 AM to 11:30 AM; Hall A
Cristina Gasparetto, Rafat Abonour, Sundar Jagannath, Brian G. Durie, Jatin J. Shah, <b>Mohit Narang</b> , Howard R. Terebelo, Kathleen Toomey, James Hardin, Lynne I. Wagner, Shankar Srinivasan, Amani Kitali, Faiza Zafar, Michael Sturniolo, <b>Robert M. Rifkin</b> .	Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.	<b>USOR Study # 9141</b> Abstract # 8023	Monday June 5, 8:00 AM to 11:30 AM; Hall A
Sundar Jagannath, Rafat Abonour, Brian G. Durie, Jatin J. Shah, Mohit Narang, Howard R. Terebelo, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, Lynne I. Wagner, Amit Agarwal, Shankar Srinivasan, Amani Kitali, Faiza Zafar, Michael Sturniolo, <b>Robert M. Rifkin</b> .	Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.	<b>USOR Study # 9141</b> Abstract # 8040	Monday June 5, 8:00 AM to 11:30 AM; Hall A
Sarit E. Assouline, <b>Kathryn S. Kolibaba, Leonard M. Klein</b> , Morton Coleman, Mitchell Reed Smith, Esteban Abella-Dominicis, Wei Ye, Wen Shi, <b>David Jacob Andorsky, Jeff Porter Sharman</b> .	Results of a phase II trial of efficacy and safety of entospletinib (ENTO) in patients with lymphoplasmacytoid lymphoma/Waldenstrom's macroglobulinemia (LPL/WM).	<b>USOR Study # 12154</b> Abstract # 7565	Monday June 5, 8:00 AM to 11:30 AM; Hall A
<b>Jeff Porter Sharman, Habte Aragaw Yimer, Michael Boxer, Nicholas DiBella</b> , Sunil Babu, Jia Li, Yong Jun Mun, Sandra L. Skettino, Alexey Valeryevich Danilov.	Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL).	<b>USOR Study # 13177</b> Abstract # 7523	Monday June 5, 8:00 AM to 11:30 AM; Hall A
Christine L. Hann, Daniel Morgensztern, Afshin Dowlati, Timothy Francis Burns, <b>Robert M. Jotte</b> , Nathan A. Pennell, <b>Stephen Lane Richey</b> , Juergen Wolf, Martin Sebastian, Tobias R. Overbeck, Mark A. Socinski, Satwant Lally, Daniel Da Costa, Sreeni Yalamanchili, D. Ross Camidge.	A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer.	<b>USOR Study # 15234</b> Abstract # TPS2598	Monday June 5, 8:00 AM to 11:30 AM; Hall A
Gregory Michael Cote, Nicole Grace Chau, <b>Alexander I. Spira, William Jeffery Edenfield</b> , Scott Andrew Laurie, <b>Donald A. Richards, Stephen Lane Richey</b> , Yuan Gao, Youzhi Li, Wei Li, Matthew Hitron, Chiang Li.	A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer.	<b>USOR Study # 14048</b> Abstract # 6032	Monday June 5, 1:15 PM to 4:45 PM; Hall A
Gregory Michael Cote, Nicole Grace Chau, <b>Alexander I. Spira, William Jeffery Edenfield</b> , Scott Andrew Laurie, <b>Donald A. Richards, Stephen Lane Richey</b> , Yuan Gao, Youzhi Li, Wei Li, Matthew Hitron, Chiang Li.	A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.	<b>USOR Study # 14048</b> Abstract # 6036	Monday June 5, 1:15 PM to 4:45 PM; Hall A
<b>Eric S. Nadler</b> , Seongjung Joo, <b>Jenny Black-Shinn, Marley Boyd</b> , Joseph Zhuo, Diana Romana Chirovsky.	Treatment patterns in recurrent/metastatic head and neck squamous cell carcinoma in the US.	<b>USOR Study # HEOR</b> Abstract # 6033	Monday June 5, 1:15 PM to 4:45 PM; Hall A

Publications		
Authors	Title	Abstract #
<b>Robert M. Rifkin</b> , Sundar Jagannath, Brian G. Durie, Jatin J. Shah, <b>Mohit Narang</b> , Howard R. Terebelo, Cristina Gasparetto, Kathleen Toomey, James W. Hardin, Lynne I. Wagner, Kejal Parikh, Safiya Abouzaid, Shankar Srinivasan, Amani Kitali, Faiza Zafar, Rafat Abonour.	Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry.	<b>USOR Study # 9141</b> Abstract # e19527
Andrea Wang-Gillam, Li-Tzong Chen, Chung-Pin Li, Gyorgy Bodoky, Andrew Dean, Kyung-Hun Lee, David Cunningham, Richard Hubner, <b>Fadi S. Braiteh</b> , J. Marc Pipas, Bruce Belanger, Floris A. de Jong, Purvi D. Mody, <b>Daniel D. Von Hoff</b> , Jens T. Siveke.	The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.	<b>USOR Study # 11031</b> Abstract # e15795
<b>Thomas H. Cartwright</b> , Thu-Cuc Nguyen, <b>Allen Lee Cohn, Donald A. Richards</b> .	Initial safety results from a randomized, phase II study of high-risk colorectal cancer patients (stage IIIC) treated with either regorafenib or standard of care (no treatment) after adjuvant FOLFOX.	<b>USOR Study # 13050</b> Abstract # e15152
<b>Charles Lance Cowey</b> , Frank Xiaoqing Liu, <b>Jenny Black-Shinn</b> , Kendall Lee Stevinson, Marley Boyd, <b>Debra A. Patt</b> , Scot Ebbinghaus.	An observational study of patients with advanced melanoma receiving pembrolizumab in a real-world U.S. community oncology practice.	<b>HEOR Study</b> Abstract # e21015
Kyle Flannery, <b>Jenny Black-Shinn, Marley Boyd, Ashish M. Kamat</b> .	Real world treatment utilization and outcomes of patients with metastatic bladder cancer by cisplatin eligibility in U.S. community oncology practice.	<b>HEOR Study</b> Abstract # e16016
Tamira Harris, <b>Lalan S. Wilfong</b> .	Designing comprehensive patient and family centered oncology care to achieve value based quality outcomes: Lessons learned from the field in creating sustainable change.	<b>HEOR Study</b> Abstract # e18225
Qinli Ma, Abiy Agiro, Anupama Kurup Acheson, Sze-Jung Wu, <b>Debra A. Patt</b> , John Barron, Alan Rosenberg, Richard L. Schilsky, Gary H. Lyman.	Neutropenia related hospitalization risk in lung cancer patients with chemotherapy.	<b>HEOR Study</b> Abstract # e18290
<b>Eric S. Nadler</b> , Janet L. Espirito, Melissa Pavilack, Marley Boyd, Andrea Leninka Vergara-Silva, Ancilla Fernandes.	Understanding treatment patterns and outcomes in patients with metastatic NSCLC treated in a US community oncology network.	<b>HEOR Study</b> Abstract # e20643

Education Sessions		
Authors	Title	Date/Time
Elad Sharon, <b>Debra A. Patt</b> , Louis Fiore, Sean Khozin.	Big Data in Oncology.	Thursday June 1, 3:00 PM to 4:15 PM
Jessica Scott, <b>Kathryn Elizabeth Hudson</b> , Mark Haykowsky, <b>Neelima Denduluri</b> .	Lifestyle Interventions to Improve Cardiorespiratory Fitness and Reduce Breast Cancer Occurrence.	Saturday June 3, 8:00 AM to 9:15 AM
<b>Debra A. Patt</b> , James Markert, Vinay K. Puduvalli, Rekha T. Chaudhary.	ASCO Town Hall: Practice Realities in a Shifting Policy Landscape.	Saturday June 3, 4:45 PM to 6:00 PM
Kelly J. Cooke, <b>Debra A. Patt</b> , Roshan Sudhir Prabhu.	Career Management: Mentorship in the Community Setting.	Sunday June 4, 4:45 PM to 6:00 PM
Jeremy Warner, Elmer Victor Bernstam, <b>Debra A. Patt</b> , Joshua Mandel.	More Medicine, Fewer Clicks: How Informatics Can Actually Help Your Practice.	Monday June 5, 3:00 PM to 4:15 PM

**Bolded text:** Investigators affiliated with US Oncology Research, The US Oncology Network and/or McKesson Specialty Health.

